The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: DNA polymerase compositions. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
See Also:
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1 which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
DNA polymerase compositions is a key innovation area in the pharmaceutical industry
DNA polymerases is a member of a family of enzymes that catalyse the synthesis of DNA molecules from nucleoside triphosphates, which are molecular precursors of DNA by the process of replication. These enzymes are essential for DNA replication and usually work in groups to create two identical DNA duplexes from single original duplex. DNA polymerase subunit Pol α initiates DNA synthesis, Pol δ synthesizes the lagging strand, and Pol ε synthesizes the leading strand. The majority of DNA replication is performed by Pol δ and Pol ε.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 100 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of DNA polymerase compositions.
Key players in DNA polymerase compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to fatty oil extraction
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| F. Hoffmann-La Roche | 487 | Unlock Company Profile |
| Thermo Fisher Scientific | 286 | Unlock Company Profile |
| GemVax & KAEL | 188 | Unlock Company Profile |
| Illumina | 128 | Unlock Company Profile |
| Invectys | 72 | Unlock Company Profile |
| New England Biolabs | 70 | Unlock Company Profile |
| Cell Signaling Technology | 69 | Unlock Company Profile |
| Compagnie Merieux Alliance | 64 | Unlock Company Profile |
| Seattle Children's Hospital | 61 | Unlock Company Profile |
| BioRad Laboratories | 54 | Unlock Company Profile |
| Adverum Biotechnologies | 48 | Unlock Company Profile |
| Pacific Biosciences of California | 44 | Unlock Company Profile |
| Spanish National Research Council | 40 | Unlock Company Profile |
| Beijing BGI-GBI Biotech | 38 | Unlock Company Profile |
| NMS Group | 38 | Unlock Company Profile |
| A. Menarini Industrie Farmaceutiche Riunite | 37 | Unlock Company Profile |
| Consejo Superior Investigacion | 36 | Unlock Company Profile |
| Takara Holdings | 35 | Unlock Company Profile |
| Opthea | 35 | Unlock Company Profile |
| City of Hope | 34 | Unlock Company Profile |
| Bio-Rad Laboratories | 33 | Unlock Company Profile |
| Danaher | 31 | Unlock Company Profile |
| OncoPlex Diagnostics | 28 | Unlock Company Profile |
| Toyobo | 27 | Unlock Company Profile |
| Solis BioDyne | 27 | Unlock Company Profile |
| Genecast | 25 | Unlock Company Profile |
| Amgen | 25 | Unlock Company Profile |
| Ultimovacs | 24 | Unlock Company Profile |
| Gilead Sciences | 22 | Unlock Company Profile |
| Ligacept | 22 | Unlock Company Profile |
| UK Research and Innovation | 21 | Unlock Company Profile |
| Astellas Pharma | 19 | Unlock Company Profile |
| Mitsui Chemicals | 19 | Unlock Company Profile |
| Debiopharm Group | 19 | Unlock Company Profile |
| Quantum-Si | 18 | Unlock Company Profile |
| Aravive | 17 | Unlock Company Profile |
| Abbott Laboratories | 17 | Unlock Company Profile |
| Sanofi | 17 | Unlock Company Profile |
| National Cancer Center | 17 | Unlock Company Profile |
| Geron | 17 | Unlock Company Profile |
| Pfizer | 16 | Unlock Company Profile |
| Qiagen | 15 | Unlock Company Profile |
| Oxford Nanopore Technologies | 15 | Unlock Company Profile |
| Twist Bioscience | 15 | Unlock Company Profile |
| Inovio Pharmaceuticals | 15 | Unlock Company Profile |
| TME Pharma | 15 | Unlock Company Profile |
| Viridos | 14 | Unlock Company Profile |
| LifeSci Index Partners | 14 | Unlock Company Profile |
| Algentech | 14 | Unlock Company Profile |
| Precigen | 13 | Unlock Company Profile |
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche (Roche) is the leading patent filer in DNA polymerase compositions. Roche is an innovative global healthcare company, whose primary focus includes haematology, infectious diseases, neurology, immunology, ophthalmology, rare diseases, respiratory, women’s health, inflammatory bowel diseases, and oncology. Currently, Roche has one marketed DNA polymerase inhibitor drug valganciclovir hydrochloride, Valcyte, for the treatment of Cytomegalovirus (HHV-5) infections. GemVax & KAEL and Invectys are the other key patent filers in DNA polymerase compositions.
In terms of application diversity, Precigen is the top company, followed by Calitor Sciences, and C. H. Boehringer Sohn. By means of geographic reach, the Seattle Children's Hospital held the top position, while Astellas Pharma and Amgen stand in the second and third position, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
